Pfizer’s CEO Albert Bourla forecasts that China will be his main competitor within five years, as the Asian nation implements a policy drive to cement its powerhouse role in the global drug innovation landscape.
Speaking at the Jefferies Global Healthcare Conference in London on 17 November, Bourla said that competition is set to move away from the traditional opposition of a Western big pharma company amid China’s significant growth in recent years.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
He said: “China [is] growing its biotech business and has an ambition to become a global player. I think they will be successful.”
China has embarked on a strategy to grow beyond its role as a popular licensing destination in recent years. In September, the Chinese government unveiled its 15th five-year plan for its biomedical industry, with aims to be more proactive on the global stage. By 2030, China wants to make and develop 25% of global first-in-class drugs. The government said it wanted to become an exporter of innovative drugs rather than a supplier of active pharmaceutical ingredients (APIs).
“By 2030, they will represent my major competition. It’s not going to be AstraZeneca or Eli Lilly. It’s going to be Chinese companies,” Bourla added.
Over the past decade, China has become a go-to port of call for Western big pharma searching for pipeline additions. Licensing deals between US and Chinese biopharma companies have significantly increased over recent years, according to analysis by GlobalData, parent company of Pharmaceutical Technology. While analysis hasn’t been conducted in 2026, estimates look like another deal inflexion is on the cards.
High-profile transactions this year include AstraZeneca’s $18.5bn obesity deal with CSPC, which was forged in January 2026, and Bristol Myers Squibb’s (BMS’s) $15.2bn deal with Jiangsu Hengrui Pharma in May 2026.
President Xi Jinping has outlined a series of initiatives to achieve this and its wider target of becoming a global pharma leader. Research and development (R&D) efforts will significantly ramp up, artificial intelligence (AI) and quantum computing will continue to be harnessed in drug discovery, and pharma ecosystems will be built beyond just pipelines.
“They are coming in at half the cost, and three or four times the speed. If we want to compete with them by 2030, we need to be half the cost, and increase speed by three or four times,” Bourla warned. “That sounds very difficult to achieve, unless AI delivers on the problems. And AI, for me, is the biggest lever to be able to build the Pfizer for the future,” he added.
Geopolitical flux raises questions
Bourla’s comments come amid a shift in political tides that play a key role in relationships between Western pharma companies and Chinese biotechs. Last month, the US Department of the Treasury proposed adding biotech to the Comprehensive Outbound Investment Security (COINS) Act. The framework expands the government’s ability to restrict or monitor US investment in sensitive technologies developed by companies listed as “ones of concern”. The Act has widely been described as primarily targeting American investment in China.
Biotech’s potential inclusion on COINS adds to a US-China pharma landscape already fraught with complications. The BIOSECURE Act came into law this year, limiting Chinese biotechs and manufacturers from accessing US funding and collaborating with domestic pharma companies using federal funds.
Then in November, a switch in US Congress arrived when the Democrats won both the Senate and the House in midterms. While analysts have said near-term pharma dynamics will largely be unaffected, this increases the focus on Trump administration policies such as China-directed investment and Most Favored Nation (MFN) deals.
